Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

OCaMIR a non-invasive early diagnostic test for ovarian cancer: A multi-cohort retrospective and prospective analysis

ABSTRACT: OCaMIR a non-invasive early diagnostic test for ovarian cancer: A multi-cohort retrospective and prospective analysis

PROVIDER: PRJNA525672 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8670070.fastq.gz	Fastqsanger.gz
	SRR8670080.fastq.gz	Fastqsanger.gz
	SRR8670090.fastq.gz	Fastqsanger.gz
	SRR8670071.fastq.gz	Fastqsanger.gz
	SRR8670081.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 31

Similar Datasets

OCaMIR a non-invasive early diagnostic test for ovarian cancer: A multi-cohort retrospective and prospective analysis

Project description:Owing to the lack of effective screening tools and early detection biomarkers, ovarian cancer (OC) still remains as a deadly disease with highest mortality among other gynecological cancers. So far there have been no attempts to discover biomarkers using early stage OC patients. MicroRNAs (miRNAs) have been recognized as great tool to develop non-invasive biomarkers in various cancers including ovarian cancer.

2020-03-06 | GSE127873 | GEO

Field test for diagnostic P deficiency genes

Project description:Field test for diagnostic P deficiency genes

2012-04-12 | E-MTAB-634 | biostudies-arrayexpress

Prospective cohort carriage study

Project description:Prospective cohort carriage study

| PRJEB53187 | ENA

A miRNA signature for early non-invasive diagnosis of pre-eclampsia

Project description:Background: Preeclampsia (PE) is a multi-systemic maternal syndrome with substantial maternal and fetal morbidity and mortality. Currently, there is no clinically viable non-invasive biomarker assay for early detection, thus limiting the effective prevention and therapeutic strategies for PE. Methods: We conducted a discovery-training-validation three-phase retrospective and prospective study with cross-platform and multicenter cohorts. The initial biomarkers were discovered and verified in tissue specimens by small RNA sequencing and qRT-PCR. A miRNA signature (miR2PE-score) was developed using the Firth’s bias-reduced logistic regression analysis, and subsequently validated in two independent multinational retrospective cohorts and two prospective plasma cohorts. Results: We initially identified five PE-associated differentially expressed miRNAs from miRNA sequencing data and subsequently validated two miRNAs (miR-196b-5p and miR-584-5p) as robust biomarkers by association analysis with clinical characteristics and qRT-PCR in tissue specimens in the discovery phase. Using the Firth’s bias-reduced logistic regression analysis, we developed the miR2PE-score for the early detection of PE. The miR2PE-score showed a high diagnostic performance with an area under the receiver operating characteristic curve (AUROC) of 0.920, 0.848, 0.864 and 0.812 in training, internal and two external validation cross-platform and multicenter cohorts, respectively. Finally, we demonstrated the non-invasive diagnostic performance of the miR2PE-score in two prospective plasma cohorts with AUROC of 0.933 and 0.787. Furthermore, the miR2PE-score revealed superior performance in non-invasive diagnosis compared with previously published miRNA biomarkers. Conclusions: We developed and validated a novel and robust blood-based miRNA signature, which may serve as a promising clinically applicable non-invasive tool for the early detection of PE.

2022-09-21 | GSE206988 | GEO

test

Project description:test test

| PRJEB44966 | ENA

Identifying urinary RNA from prospective urine as non-invasive biomarkers for kidney transplant patients

Project description:To identify urinary RNA from prospective urine as non-invasive biomarkers for kidney transplant patients

2019-03-16 | GSE128347 | GEO

test

Project description:test

| PRJEB30831 | ENA

test

Project description:test